ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,803.83
-0.40%
US Tech 100
20,118.00
-0.84%
Dow Jones
42,082.12
0.34%
Brent Oil
80.28
-0.42%
Bitcoin
92,116.55
-2.51%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Canada
  5. TSX

  6. Medicenna Therapeutics Corp (MDNA) Quote

Medicenna Therapeutics Corp

Medicenna Therapeutics Corp (MDNA)

TSX
1.30
-0.07
( -5.11% )
Updated: 12:01:43
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
1.30
Bid
1.30
Ask
1.31
Volume
31,014
1.30 Day's Range 1.39
0.41 52 Week Range 2.98
Market Cap
90.528M
Previous Close
1.37
Open
1.39
Last Trade
300
@
1.3
Last Trade Time
12:01:43
Financial Volume
-
VWAP
-
Average Volume (3m)
85,309
Shares Outstanding
69,637,000
Dividend Yield
-
PE Ratio
-3.58
Earnings Per Share (EPS)
-0.37
Revenue
-
Net Profit
-25.47M

About Medicenna Therapeutics Corp

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.medicenna.com
Headquarters
Toronto, Ontario, Can
Founded
-
Medicenna Therapeutics Corp is listed in the Biological Pds,ex Diagnstics sector of the Toronto Stock Exchange with ticker MDNA. The last closing price for Medicenna Therapeutics was $1.37. Over the last year, Medicenna Therapeutics shares have traded in a share price range of $ 0.41 to $ 2.98.

Medicenna Therapeutics currently has 69,637,000 shares outstanding. The market capitalization of Medicenna Therapeutics is $95.40 million. Medicenna Therapeutics has a price to earnings ratio (PE ratio) of -3.58.

Ask ADVFN Intelligence (AI)

MDNA Latest News

More News

Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Single-agent MDNA11 was more effective than a combination of immune checkpoint inhibitors (anti-mPD1 and anti-mCTLA4) in preventing metastasis and achieving long-term survival in an aggressive...

December 13 2024
GlobeNewswire Inc.

Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study

70-year-old patient with advanced chemo-refractory anal cancer achieves complete response (CR) in 8 weeks when treated with MDNA11 in combination with Merck’s (known as MSD outside of the US and...

December 05 2024
GlobeNewswire Inc.

Updated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference

TORONTO and HOUSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company...

November 27 2024
GlobeNewswire Inc.

Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)

MDNA11 shows significant survival benefits in preclinical glioblastoma models, expanding CD8+ T and NK cells Bizaxofusp selectively targets human tumor cells and immune-suppressive cells...

November 25 2024
GlobeNewswire Inc.

Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update

MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose expansion cohort among patients with cancer progression...

November 15 2024
GlobeNewswire Inc.

Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS)

TORONTO and HOUSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company...

November 13 2024
GlobeNewswire Inc.

Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (pembrolizumab) at the 39th Annual Meeting of SITC

Single-agent MDNA11 shows a 30% objective response rate (3 of 10) in the monotherapy dose expansion cohort among patients with advanced and/or metastatic solid tumors who had disease progression...

November 11 2024
GlobeNewswire Inc.

Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

   MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” BiSKIT (Bifunctional SuperKine for ImmunoTherapy), engineered to deliver an anti-PD1-IL-2 Superkine (anti-PD1-IL-2SK) to the tumor...

November 08 2024
GlobeNewswire Inc.

OTC Markets Group Welcomes Medicenna Therapeutics Corp. to OTCQX

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Medicenna...

October 15 2024
GlobeNewswire Inc.

Medicenna to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Updated clinical results to be presented from the ongoing Phase 1/2 ABILITY-1 study of MDNA11 in advanced or metastatic solid tumors Preclinical data on MDNA113, Medicenna's first-in-class...

October 04 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.3-18.751.61.631.3981171.43619148CS
4-0.48-26.96629213481.781.981.3774791.5929511CS
12-0.92-41.44144144142.222.621.27853091.84420935CS
26-0.85-39.53488372092.152.621.27738571.98755074CS
520.89217.0731707320.412.980.411020521.85834982CS
156-0.71-35.32338308462.012.980.215635031.42317853CS
260-1.42-52.20588235292.727.250.215723242.7570715CS

MDNA - Frequently Asked Questions (FAQ)

What is the current Medicenna Therapeutics share price?
The current share price of Medicenna Therapeutics is $ 1.30
How many Medicenna Therapeutics shares are in issue?
Medicenna Therapeutics has 69,637,000 shares in issue
What is the market cap of Medicenna Therapeutics?
The market capitalisation of Medicenna Therapeutics is CAD 95.4M
What is the 1 year trading range for Medicenna Therapeutics share price?
Medicenna Therapeutics has traded in the range of $ 0.41 to $ 2.98 during the past year
What is the PE ratio of Medicenna Therapeutics?
The price to earnings ratio of Medicenna Therapeutics is -3.58
What is the reporting currency for Medicenna Therapeutics?
Medicenna Therapeutics reports financial results in CAD
What is the latest annual profit for Medicenna Therapeutics?
The latest annual profit of Medicenna Therapeutics is CAD -25.47M
What is the registered address of Medicenna Therapeutics?
The registered address for Medicenna Therapeutics is 200 - 1920 YONGE STREET, TORONTO, ONTARIO, M4S 3E2
What is the Medicenna Therapeutics website address?
The website address for Medicenna Therapeutics is www.medicenna.com
Which industry sector does Medicenna Therapeutics operate in?
Medicenna Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ADCOAdcore Inc
$ 0.29
(31.82%)
639.98k
OPTOptiva Inc
$ 5.04
(29.56%)
100
DII.ADorel Industries Inc
$ 4.99
(24.75%)
300
FLNTFlint Corporation
$ 0.03
(20.00%)
10.5k
DIAMStar Diamond Corporation
$ 0.03
(20.00%)
153.7k
SAMStarcore International Mines Ltd
$ 0.125
(-13.79%)
15.61k
AFNAg Growth International Inc
$ 40.98
(-13.23%)
327.73k
YRBYorbeau Resources Inc
$ 0.035
(-12.50%)
25.76k
THTheratechnologies Inc
$ 2.39
(-11.15%)
40.01k
ESMEuro Sun Mining Inc
$ 0.04
(-11.11%)
22.09k
TDToronto Dominion Bank
$ 78.46
(0.33%)
7.4M
BTEBaytex Energy Corp
$ 3.97
(1.28%)
3.95M
BCEBCE Inc
$ 33.34
(0.73%)
3.02M
WNDRWonderFi Technologies Inc
$ 0.26
(-8.77%)
2.83M
SUSuncor Energy Inc
$ 57.87
(1.88%)
2.77M

Discussion

View Full Feed
Budots Budots 3 minutes ago
$CBDW is excited to express its strong support for strategic investment target Adnexus Biotechnologies Inc. following the company's groundbreaking announcement of Trapicolast, a pioneering antimalarial drug developed through its innovative AI-powered Sutra™ platform. https://finance.yahoo.com/news/1
CBDW
dexprs dexprs 3 minutes ago
TD Cowen Maintains Buy on BellRing Brands, Raises Price Target to $86
doc2016 doc2016 3 minutes ago
744: message passing protocol for parallel computing. first to the second of 744 family. . from gemini ai 1.5 pro.:
"
cuda-q and distributed networked node connectivity?



You're hitting on a really fascinating area where cutting-edge technology intersects
getmoreshares getmoreshares 3 minutes ago
5's cleared-- 138m bid at 4-- 42m ask at 6
CGAC
Stock_Barber Stock_Barber 4 minutes ago
Can't wait to see the excuses that will accompany the 10Q!

Poo's keyboard is certainly getting a workout in preparation...


https://investorshub.advfn.com/uimage/uploads/2022/4/11/ehfqdPoop.jpg
DBMM
Budots Budots 4 minutes ago
$CBDW is excited to express its strong support for strategic investment target Adnexus Biotechnologies Inc. following the company's groundbreaking announcement of Trapicolast, a pioneering antimalarial drug developed through its innovative AI-powered Sutra™ platform. https://finance.yahoo.com/news/1
CBDW
SANDRA11 SANDRA11 4 minutes ago
Thank you for the heads up. That won't change anything. It is still a TURD. 
REPO
ProfitChaser ProfitChaser 4 minutes ago
Those call options looking pretty cheap here. I dont normally play the options as I am almost clueless what to do with them LOL. I did grab a few of the 3 and 4 dollar June calls today tho just incase.
fung_derf fung_derf 4 minutes ago
If you thought the stock was truly going up, it wouldn't matter. This still hasn't broken through resistance. Perhaps you don't believe it can.
Anyone who thinks this stock is going to rocket isn't worried about saving tenths of cents.
Are you sure you want to blame others? Your excuse
CYDY
sweet crude sweet crude 4 minutes ago
AI Data Centers: $ELEK, $MLRT

Next Realm AI Expands Private Data Center Initiative for Specialized AI Applications

(NEW YORK)–Next Realm AI, a technology consulting firm focused on the commercial development of artificial intelligence and data analytics solutions, is ad
ELEK MLRT
longago longago 4 minutes ago
Looking at the 10K I think they spent about $150K for the assets they bought.

If they used undervalued stock (selling for less than Tangible Book Value) rather than a small part of the cash balances they have built, there should be a shareholder revolt.
RJDG
abh3vt abh3vt 4 minutes ago
Hi Nelson, I agree this is a bit confusing re: KINS shareholder update. The questions I have after reading this are: How much of the 0.28 increase is actually an increase from the previous guidance clarification they gave back in November? Or was it partly baked in back then because they probabl
oceans11 oceans11 4 minutes ago
And the pump continues with the old  "reverse psychology" con, LOL
Classic Monday buy signal, and green so far.
Looks like everybody on the board is finally on board for the ride.
Kudos!

DPLS
exwannabe exwannabe 5 minutes ago
If you can edit real fast, might add ANVX to the post :-)
NWBO
Zorax Zorax 5 minutes ago
Can anyone honestly believe a billard bar bought a defunct penny stock and is doing nothing with it for over a year, except maybe money laundering?
ACCR
sweet crude sweet crude 5 minutes ago
AI Data Centers: ELEK, MLRT

Next Realm AI Expands Private Data Center Initiative for Specialized AI Applications

(NEW YORK)–Next Realm AI, a technology consulting firm focused on the commercial development of artificial intelligence and data analytics solutions, is adva
ELEK MLRT
getmoreshares getmoreshares 5 minutes ago
up now-42m ask at 6
CGAC
pual pual 5 minutes ago
I know that but I do not know (may be I should) why the $3 pps is so critical to start with ???
GRST
Smartypants2 Smartypants2 5 minutes ago
How can you say that when Killa claims NEXBOARD isn't real and Q says it's all part of a scam? ("Not a single person here is debating if Nexboard is real (or) the unbelievable potential it has.")
XERI
misterfishman misterfishman 6 minutes ago
phahahahahahahahahahahahahahahahahahahahahahahahahehehehehehehehehohohohohohohohohohohohohohohohohohhahahahahahahahahahsaaaa. if got to waist your money then throw it away with a smile hahahahahahaha lol.
NNRX
firebag1 firebag1 6 minutes ago
hope she runs before the big do, then catches more fire!!
SANA
astroblaster astroblaster 6 minutes ago
Fmnj no longer is reporting anything to otcmarkets.com...will be totally delisted soon.  
FMNJ
ORCA ORCA 7 minutes ago
SELL BRO SELL.THERE IS NO EVENT FOR NOW.UNTIL THE END OF MARCH YEARLY REPORT.IMAGINE IF OTIKO LOST MONEY???LOL.THE REASON I KEEP FLIPPING IS BECAUSE YOU CAN NOT TRUST THIS POS OTIKO.
HE NEVER COMES THROUGH.AS LONG AS OTIKO IS CEO I WILL KEEP FLIPPING.NOW LOOKING TO BUY BACK IN MUCH LOWER AGAI
VDRM
Big Benny Big Benny 7 minutes ago
I am assuming that most of you are thinking that the volume is up as a result of ABQQ buying back shares, correct? MMs must be in on the thing?

BB
ABQQ
firebag1 firebag1 7 minutes ago
just keep slapping the ask get rid of these godddaaaamn 1 tick flipper dicks
CGAC

Your Recent History

TSX
MDNA
Medicenna Therapeutics
BIT
NICK
ETFS Nickel
BIT
STAW
Amundi S&P Global Consum...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads